Search Results - "Kropf, P.L."

Randomized Phase 2 Study of Guadecitabine in Patients with HMA-Naive Higher Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) by Savona, M.R, Garcia-Manero, G, Roboz, G.J, Walsh, K.J, Kropf, P.L, Issa, J.P, O’Connell, C.L, Tibes, R, Yee, K.W.L, Stock, W, Lunin, S, Berdeja, J.G, Naim, S, Hao, Y, Azab, M, Kantarjian, H

Get full text

Dasatinib promotes ATRA-induced differentiation of AML cells by Kropf, P L, Wang, L, Zang, Y, Redner, R L, Johnson, D E

Get full text

60 - Randomized Phase 2 Study of Guadecitabine in Patients with HMA-Naive Higher Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) by Savona, M.R., Garcia-Manero, G., Roboz, G.J., Walsh, K.J., Kropf, P.L., Issa, J.P., O’Connell, C.L., Tibes, R., Yee, K.W.L., Stock, W., Lunin, S., Berdeja, J.G., Naim, S., Hao, Y., Azab, M., Kantarjian, H.

Get full text

S879 RESULTS OF ASTRAL‐1 STUDY, A PHASE 3 RANDOMIZED TRIAL OF GUADECITABINE (G) VS TREATMENT CHOICE (TC) IN TREATMENT NAÏVE ACUTE MYELOID LEUKEMIA (TN‐AML) NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY (IC) by Fenaux, P., Gobbi, M., Kropf, P.L., Mayer, J., Roboz, G.J., Döhner, H., Krauter, J., Döhner, K., Robak, T., Kantarjian, H., Novak, J., Jedrzejczak, W., Thomas, X., Ojeda‐Uribe, M., Miyazaki, Y., Min, Y. H., Yeh, S.‐P., Brandwein, J., Gercheva‐Kyuchukova, L., Demeter, J., Griffiths, E., Yee, K., Azab, M., Issa, J.‐P.

“…Background: G is a next generation hypomethylating agent (HMA) given subcutaneously (SC) which provides prolonged in vivo exposure to its active metabolite…”
Get full text

Src family kinase gene targets during myeloid differentiation: identification of the EGR-1 gene as a direct target by Jones, J E, Wang, L, Kropf, P L, Duan, R, Johnson, D E

Get full text